Escalating therapy of cutaneous side effects of EGFR inhibitors: Experience of German reference centers;Eskalationstherapie kutaner Nebenwirkungen von EGFR-Inhibitoren: Erfahrungen deutscher Referenzzentren

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 8, 2012, Pages 559-562

  Homey, Bernhard ^a   Gerber, Peter Arne ^a   Wollenberg, Andreas ^b   Dirschka, Thomas ^c   Hassel, Jessica C ^d   Bölke, Edwin ^a   Hauschild, Axel ^e   Gutzmer, Ralf ^f  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Dermatologische Praxis Auf der Kö88   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cetuximab; erlotinib; paronychia; pruritus; radiation dermatitis; rash; rhagades

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; CETUXIMAB; CICLOPIROXOLAMINE; CLOTRIMAZOLE; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FOLIC ACID; IRINOTECAN; ISOTRETINOIN; KETOCONAZOLE; METRONIDAZOLE; MINOCYCLINE; OCTENIDINE; PERMETHRIN; PREDNICARBATE; RETINOID; TETRACYCLINE DERIVATIVE;

ACNE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; COLON CARCINOMA; CONSENSUS; CORTICOSTEROID THERAPY; DERMATOLOGIST; DISEASE PREDISPOSITION; DRUG ERUPTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GERMANY; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MALASSEZIA FOLLICULITIS; OINTMENT; PAPULOPUSTULAR RASH; PARONYCHIA; PATIENT CARE; PERSONAL EXPERIENCE; PRURITUS; QUALITY OF LIFE; RADIATION DERMATITIS; RASH; REVIEW; SKIN ATROPHY; SKIN PAIN; SQUAMOUS CELL CARCINOMA; TOPICAL TREATMENT; TRICHORRHEXIS; UNSPECIFIED SIDE EFFECT; XEROSIS;

EID: 84864422683     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2012.07948.x     Document Type: Review

References (19)

1. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC,. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76. (Pubitemid 34204207)
2. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A,. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010; 18: 509-22.
3. Gutzmer R, Becker JC, Enk A, Garbe C, Hauschild A, Leverkus M, Reimer G, Treudler R, Tsianakas A, Ulrich C, Wollenberg A, Homey B,. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 2011; 9 (3): 195-203.
4. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A,. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22 (3): 524-35.
5. Segaert S, Van Cutsem E,. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33. (Pubitemid 41222414)
6. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA,. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23: 165-74. (Pubitemid 41702635)
7. Eilers RE, Jr., Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME,. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102: 47-53.
8. Gerber PA, Kukova G, Buhren BA, Homey B,. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011; 222: 144-7.
9. Cuetara MS, Aguilar A, Martin L, Aspiroz C, del Palacio A,. Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis. Br J Dermatol 2006; 155: 477-9. (Pubitemid 44050590)
10. Forton F, Seys B,. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993; 128: 650-9. (Pubitemid 23172024)
11. Gerber PA, Enderlein E, Homey B,. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 2008; 26: 2790-2.
12. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J,. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153: 849-51. (Pubitemid 41415923)
13. Kudo K, Fujiwara K, Tsushima M, Mizuta M, Matsuo K, Yonei T, Sato T,. Toxicity manifesting as cosmetic hair alterations during erlotinib treatment. Acta Oncol 2011; 50: 146-8.
14. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME,. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007; 72: 152-9. (Pubitemid 351161602)
15. Gerber PA, Buhren BA, Cevikbas F, Bölke E, Steinhoff M, Homey B,. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010; 63: 163-5.
16. Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 2010; 24: 958-60.
17. Bernier J, Russi EG, Homey B, Merlano MC, Mesia R, Peyrade F, Budach W,. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011; 22: 2191-200.
18. Bolke E, Gerber PA, Lammering G, Peiper M, Müller-Homey A, Pape H, Giro C, Matuschek C, Bruch-Gerharz D, Hoffmann TK, Gripp S, Homey B, Budach W,. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184: 105-10. (Pubitemid 351231657)
19. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK,. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.